Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia by Gwee, Kok-Ann
JNM Journal of Neurogastroenterology and Motility 
Review
30
J Neurogastroenterol Motil,  Vol. 16  No. 1 January,  2010 
DOI: 10.5056/jnm.2010.16.1.30
ⓒ 2010 The Korean Society of Neurogastroenterology and Motility
J Neurogastroenterol Motil,  Vol. 16  No. 1 January,  2010
www.jnmjournal.org
Post-Infectious Irritable Bowel Syndrome, an 
Inflammation-Immunological Model with 
Relevance for Other IBS and Functional 
Dyspepsia
Kok-Ann Gwee, FRCP, Ph.D.
Yong Loo Lin School of Medicine, National University of Singapore and Gleneagles Hospital, Singapore
ㅋ
This review presents studies that support an inflammation-immunological model for the pathogenesis of post-infectious irrita-
ble bowel syndrome (IBS), and highlights recent studies that support a similar disease model in non-post-infectious IBS, in par-
ticular, diarrhoea-predominant IBS, as well as in post-infectious functional dyspepsia. These recent studies are highlighted to 
demonstrate that one line of research in functional gastrointestinal disorders has moved away from the old psychosomatic 
concepts. It is hoped that this will encourage future students of this field to explore the role of immunological events.
(J Neurogastroenterol Motil 2010;16:30-34)
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Introduction
The irritable bowel syndrome (IBS) is a condition that af-
flicts 10-20% of the population with a variable combination of ab-
dominal pain, bloating, constipation, and diarrhoea. To patients, 
scientists and doctors unfamiliar with recent research, it is a con-
dition with no known cause, no animal models, no biomarkers, 
and no effective treatment. Perhaps because of this, IBS, as well 
as other functional gastrointestinal disorders, are often perceived 
to be psychological disorders. However, recent studies on a sub-
set of patients who develop IBS following an episode of gastro-
intestinal infection, has allowed us to articulate an inflamma-
tion-immunological model that has now been applied as well to 
other groups of IBS and also to functional dyspepsia. In this re-
view, I will first present the research in post-infectious IBS that 
supports this model, and then draw attention to recent research 
that has implicated similar pathogenic factors in non-post-in-
fectious IBS and functional dyspepsia. 
Post-Infectious IBS (PI-IBS)
Studies of PI-IBS have provided us with one of the best 
working model for understanding the aetiopathogenesis of IBS. Inflammation-Immunological Model for FGID
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In the early studies from Sheffield, patients with acute gastro-
enteritis were followed prospectively to document the develop-
ment of IBS and to identify predisposing factors. Stress, as repre-
sented by the presence of recent traumatic life events, and a neu-
rotic personality trait, were found to be the best predictors of who 
might develop IBS post-infection (Table 1).
1 At 3 months 
post-infection, both, patients who had developed IBS and pa-
tients who were asymptomatic, demonstrated accelerated colonic 
transit and increased rectal sensitivity compared with uninfected 
controls, with the IBS patients having more severe disturbances.
2 
Rectal biopsies were obtained from a number of patients to study 
inflammatory markers. Comparing PI-IBS patients with post-in-
fection controls and healthy non-infection controls, we found that 
IBS patients had relatively greater mucosal cellularity which we 
interpreted as an indication of a subcolitic inflammatory process. 
To further support a pathogenic role for inflammation, we dem-
onstrated increased expression of pro-inflammatory cytokine in-
terleukin 1β m RNA in rectal biopsies taken at 3 months post-in-
fection in PI-IBS patients which was not observed in post-in-
fection patients without IBS.
3 Putting all these data together we 
proposed a bio-psychophysiological model for PI-IBS. An epi-
sode of infectious diarrhoea may produce changes in the gastro-
intestinal physiology that predispose to the development of IBS 
symptoms like diarrhoea and pain. However, the manifestation of 
IBS develops when psychological factors exist in association with 
more severe inflammatory and physiological disturbances. This 
could explain why only a fraction of patients with infection devel-
op IBS. Conversely, this could also be used to explain why the 
majority of patients with psychiatric disturbances do not com-
plain of IBS symptoms. 
Studies from other centres support this dynamic and inter-
active model. Spiller’s group from Nottingham studied a group 
of patients with Campylobacter jejuni gastroenteritis.
4 Serial rectal 
mucosal biopsies taken post-infection demonstrated increased 
counts of intra-epithelial lymphocytes and enteroendocrine cells 
at 2 weeks, that gradually normalised over 12 weeks, but ap-
peared to persist in patients with PI-IBS. Furthermore, PI-IBS 
patients had significantly elevated CD3
+ and CD8
+ lympho-
cytes. In these post-Campylobacter patients, intestinal permeability 
was also observed to be increased at 6 weeks and 12 weeks 
post-infection, even in some patients who were asymptomatic. In 
a subsequent study from Nottingham, it was reported that the in-
testinal permeability of PI-IBS subjects was increased in the 
proximal small intestine compared with controls, but this was not 
as severe as diarrhoea predominant IBS without a history of 
infection.
5 In another series of PI-IBS, Marshall and colleagues 
from Ontario, Canada, studied a cohort of patients involved in a 
large waterborne outbreak of gastroenteritis, and found increased 
intestinal permeability in those who developed IBS compared 
with non-IBS controls.
6 In animal models, stress has been dem-
onstrated to increase intestinal permeability with enhanced 
trans-epithelial passage of luminal antigens.
7 In a recent study 
women exposed to moderate background stress (in the form of 
recent life events), demonstrated a defective jejunal epithelial re-
sponse (increased albumin permeability) to stimuli (cold pain 
stress) that could predispose them to gut mucosal inflammation 
(increased luminal tryptase and α-defensins release).
8
A study from China followed a large cohort of patients who 
had presented with Shigella dysentery between April and October 
1998, and their family members who had not suffered dysentery.
9 
Biopsy specimens were taken from the terminal ileum and rec-
tosigmoid regions. In post-Shigella IBS patients increased IL1β 
m RNA expression was observed in the terminal ileum and 
rectosigmoid. Interestingly, they also found increased numbers of 
mast cells in biopsies taken from the terminal ileum of both 
PI-IBS as well as non-post infectious IBS (non-PI-IBS) patients, 
compared with controls. Furthermore, in the samples from these 
IBS patients, both PI-IBS and non-PI-IBS, they observed an in-
creased density of nerve fibres in the vicinity of mast cell 
collections. At the same time, in Bologna, Barbara et al. had dem-
onstrated a correlation between abdominal pain and the proximity 
of mast cells to neurons in the distal colonic mucosa in a non-spe-
cific group of IBS patients.
10 Recently, in a study from Korea in-
volving a small number of PI-IBS patients, increased numbers of 
enterochromaffin cells, mast cells, and lamina propria T lympho-
cytes were also reported in biopsies taken from the rectum.
11 
Non-Post-Infectious IBS (majority
  diarrhoea-predominant IBS)
The idea that IBS could be an inflammatory disorder has 
now been extended to other forms of IBS, and in particular diar-
rhoea predominant IBS (D-IBS). Chadwick et al, reported that 
almost 90% of a group of IBS patients (55% had D-IBS, 36% 
had PI-IBS) showed evidence of immune activation regardless of 
the type of onset.
12 The authors found higher numbers of CD25
+ 
cells in IBS patients compared with asymptomatic controls. 
CD25
+ cells are regulatory T cells that are considered important 
in the prevention of autoimmunity, as well in controlling in-
flammatory responses in the gut; their absence in mice leads to Kok-Ann Gwee
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Table 1. Summary of Inflammatory-Immune Activation Markers in FGID Studies 
Post-Infectious IBS Diarrhoea predominant IBS Functional dyspepsia
Gwee KA
1-3
  Rectal mucosa lamina propria chronic 
inflammatory cells, IL-1β mRNA
Spiller,
4 Dunlop SP
5
  Rectal mucosa lamina propria T-lymphocytes 
CD3
+, CD8
+, enterochromaffin cells
Wang LH
9
  Rectosigmoid mucosa IL-1β mRNA
  Terminal ileum mast cells, IL-1β mRNA
Lee KJ
11
  Rectal mucosa enterochromaffin cells, mast 
cells, T-lymphocytes
Chadwick VS
12
  Colonic mucosa T lymphocyte CD25
+
Barbara G
10 (IBS-D 50%, IBS-C 50%)
  Colonic mucosa mast cells
Guilarte M
13
  Jejunal mast cells, intraepithelial lymphocytes 
CD3
+
Ohman L
15
  Peripheral blood lymphocytes integrin β7
  Colonic mucosal endothelial MAdCAM-1
Langhorst J
16
  Fecal HBD-2
  Colonic epithelial enterocytes HBD-2 peptide 
Liebregts T
17
  Peripheral blood monocytes TNFα, IL-1β, 
IL-6, E. coli LPS induced TNFα 
Wang LH
9
  Terminal ileum mast cells
Lee KJ
11
  Rectal mucosa mast cells
Hanevik K
23 (Post-Giardia FD)
  Duodenal inflammation
Kindt S
25 (Post-infectious FD)
  Duodenal T cells, CD8
+ aggregate
Li WG
26
  Gastric mast cells
Talley NJ
27, Walker MM28 (FD, 
  post-infection status)
  Duodenal mucosal eosinophilia
IBS, irritable bowel syndrome; FD, functional dyspepsia; LPS, lipopolysaccharide.
spontaneous colitis. The increased presence of CD25
+ cells in 
IBS raises the possibility that there is auto- or exogenous antigen 
challenge in these patients, and that the CD25
+ cells are prevent-
ing the progression to a more florid inflammatory response. In 
another study involving D-IBS patients (30% with PI-IBS) in-
tra-epithelial CD3
+ lymphocytes were also found to be increased 
in jejunal biopsies.
13 In addition, this group of D-IBS patients al-
so presented evidence of mast cell involvement as evidenced by 
markedly increased mast cell numbers in the jejunal biopsies as 
well as higher jejunal fluid tryptase concentrations, when com-
pared with healthy controls. In a study involving a highly selected 
group of ten severe IBS patients, full thickness biopsy was ob-
tained from the jejunum laparoscopically and examined for and 
shown to have low grade infiltration of lymphocytes in the myen-
teric plexus.
14
There is dynamic evidence of intestinal immune activation in 
IBS. Ohman et al. from Sweden provided evidence of an aug-
mented cell-mediated intestinal immune response.
15 Peripheral 
blood lymphocyte were examined for T-cell expression of in-
tegrin β7, while colonic biopsies were examined for endothelial 
expression of mucosal addressin cell adhesion molecule-1 
(MAdCAM-1), in samples taken from IBS patients (60% 
D-IBS), ulcerative colitis patients and asymptomatic patients 
with a negative colonoscopy for other indications. T lymphocytes 
that have been activated in gut-associated lymph nodes express 
integrin β7 which mediates homing to intestinal mucosa by bind-
ing to its endothelial expressed ligand MAdCAM-1. In this 
study IBS patients had an increased frequency of integrin β7 and 
MAdCAM-1 resembling that seen in patients with ulcerative 
colitis. 
Another study provides evidence of activation of the mucosal 
innate defence system by studying human defensins which are 
human antimicrobial protein induced by probiotic micro-
organisms and pro-inflammatory cytokines. In particular, human 
beta-defensin-2 (HBD-2) has been reported to be expressed in 
active intestinal inflammation in ulcerative colitis (UC). In the 
study by Langhorst, faecal HBD-2 levels were measured by en-
zyme-linked immunosorbent assay (ELISA), while colonic biop-
sies were tested for HBD-2 peptides by immunohistoche-
mistry.
16 Compared with healthy controls, patients with UC and 
IBS (all of whom had diarrhoea) were found to have elevated 
HBD-2 faecal levels, and in these patients beta-defensin 2 pep-
tides were demonstrated in colonic epithelial enterocytes. These 
results support a pro-inflammatory response in IBS patients.
In another recent study, Liebregts et al., examined peripheral 
blood mononuclear cell (PBMC) production of pro-inflamma-Inflammation-Immunological Model for FGID
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tory cytokines TNF-α, IL-1β and IL-6 in IBS patients as a 
group compared with healthy controls.
17 Of particular interest 
was that patients with diarrhoea type IBS, of which PI-IBS 
formed a substantial number, demonstrated increased basal and 
Escherichia coli (E. coli) lipopolysaccharide-induced production of 
TNF-α. Furthermore, there was a positive correlation of TNF-
α production with anxiety scores. 
As the production of cytokines is under genetic control, it is 
possible to study the role of genetics by evaluating the genotypes 
for various pro- and counter-inflammatory cytokines. Two stud-
ies have reported lower frequency in IBS patients of genotypes 
promoting production of IL-10 which is a counter-inflammatory 
cytokine.
18,19 In one study, increased frequency of genotypes that 
promoted the production of TNF-α, a pro-inflammatory cyto-
kine, was reported in IBS patients.
19 In this study, PI-IBS pa-
tients comprised 21% of the study group; comparing PI-IBS 
with non-PI-IBS patients the frequency of genotypes for IL-10 
and TNF-α appeared similar between the two groups. However, 
when comparing predominant bowel habits, D-IBS patients had 
significantly higher prevalence of TNF-α producer genotypes. A 
recent study employing microarray expression profiling has iden-
tified differential expression of genes associated with the host mu-
cosal immune response to microbial pathogens, between IBS pa-
tients and healthy controls.
20 
Functional Dyspepsia
In 2002, an outbreak of Salmonella gastroenteritis occurred in 
a Spanish village as a result of contamination of cream cakes from 
a bakery.
21 When these subjects were followed up prospectively, 
it was found that Salmonella gastroenteritis was a significant risk 
factor not only for IBS, but also for functional dyspepsia (FD). 
Furthermore, a substantial number of subjects had an overlap 
syndrome of IBS and FD. It was observed that while over time 
the number of subjects who had dyspepsia alone declined pro-
gressively, the number of FD-IBS subjects appeared to remain 
fairly stable.
A paper from Norway reported the outcome of an outbreak 
of waterborne giardiasis in Bergen that occurred in 2004.
22 Out 
of a total of 1,300 symptomatic cases with Giardia lamblia identi-
fied in stool samples, 139 had persistent symptoms despite several 
treatment courses. An estimated two thirds of these patients had 
overlapping IBS and FD. Twenty-two post-Giardia infection pa-
tients with IBS by Rome II criteria and 19 patients who had re-
covered from Giardia infection after treatment with metronida-
zole, were enrolled into a meat soup gastric emptying study. The 
post-Giardia IBS patients had lower drinking capacity and slower 
gastric emptying. In some patients sequential duodenal biopsies 
demonstrated microscopic inflammation that subsided with time 
despite the persistence of symptoms.
23 In a long term follow-up 
study of 82 patients from this post-Giardia IBS cohort, the au-
thors reported that close to 60% reported exacerbation of their 
symptoms by specific foods.
24 
Beyond these two well defined cohorts, studies of what is 
termed post-infectious functional dyspepsia (PI-FD), are more 
limited, but nevertheless provides support for an inflammatory 
and immunological mechanism in the pathogenesis. In a recent 
study from Belgium, duodenal biopsies were obtained from pa-
tients with presumed PI-FD and patients with unspecified FD 
(U-FD).
25 Focal aggregates of T cells and focal CD8
+ ag-
gregates were found in PI-FD but not in U-FD patients. 
Furthermore, gastric emptying was studied, and found to be de-
layed in patients with these focal aggregates. In a study from 
Shanghai, 550 patients with acute gastrointestinal infection were 
followed-up for half a year, and the prevalence of PI-FD was esti-
mated to be 6.7% and epigastric pain, epigastric burning sensa-
tion, and early satiety were the major symptoms in these 
patients.
26 In gastric biopsies from PI-FD patients, the number 
of activated mast cells, as evidenced by the total amount of tryp-
tase and histamine released in the gastric mucosa, was reported to 
be higher than non-PI-FD patients and healthy controls. 
Furthermore, the number of mast cells located within 5 microns 
of nerve fibers was significantly higher in PI-FD patients than in 
the other two groups.
In a large study from Sweden, duodenal biopsies were ob-
tained from asymptomatic and symptomatic subjects drawn from 
a large community cohort offered screening gastroscopy.
27,28 
Insufficient information was provided to determine the proportion 
of subjects with PI-FD. However, unusually, Helicobacter pylori 
infection was significantly less common in their FD subjects than 
subjects with IBS criteria. In their cohort, FD subjects had duo-
denal eosinophilia compared to asymptomatic controls, and an as-
sociation with early satiety was reported.
Conclusion
These recent studies enable us to better conceptualise how 
immunological events may lead to the development of IBS and 
FD, and how environmental, genetic and psychological factors 
modulate the outcome. They also help us to move beyond the old Kok-Ann Gwee
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paradigm of functional and organic. The hope is that with this 
more sophisticated approach we can overcome the prejudices as-
sociated with the psychosomatic model, and become better at 
identifying biomarkers, and at developing animal models and 
more effective treatments, in what were traditionally functional 
gastrointestinal disorders. 
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